Revolution Medicines Inc (RVMD) News

Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress

REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a...

Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024

REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a...

Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

REDWOOD CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a...

Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

Two original papers in Nature highlight the discovery and translational implications of RMC-7977, a RAS(ON...

Revolution Medicines to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a...

Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024

REDWOOD CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

Form S-8 - Securities to be offered to employees in employee benefit plans

Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress

REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a...

Form 8-K - Current report

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024

REDWOOD CITY, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a...

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]